Opposite Clinical Phenotypes of Glucokinase Disease: Description of a Novel Activating Mutation and Contiguous Inactivating Mutations in Human Glucokinase (GCK) Gene

Fabrizio Barbetti, Nadia Cobo-Vuilleumier, Carlo Dionisi-Vici, Sonia Toni, Paolo Ciampalini, Ornella Massa, Pablo Rodriguez-Bada, Carlo Colombo, Lorenzo Lenzi, Maria A. García-Gimeno, Francisco J. Bermúdez-Silva, Fernando Rodríguez de Fonseca, Patrizia Banin, Juan C. Aledo, Elena Baixeras, Pascual Sanz, and Antonio L. Cuesta-Muñoz

Bambino Gesù Pediatric Hospital (F.B., C.D.-V., P.C., O.M., C.C.), Istituto di Ricovero e Cura a Carattere Scientifico, Rome 00164, Italy; Department of Internal Medicine (F.B.), University of Rome Tor Vergata, Rome 00134, Italy; Laboratory of Molecular Endocrinology and Metabolism (F.B.), S Raffaele Biomedical Park Foundation, Rome 00128, Italy; Center for the Study of Pancreatic β-Cell Diseases (N.C.-V., P.R.-B., F.J.B.-S., F.R.d.F., J.C.A., E.B., A.L.-C.-M.). Instituto Mediterráneo para el Avance de la Biotecnología y la Investigación Sanitaria Foundation and Carlos Haya Hospital, Málaga 29010, Spain; Regional Center for Juvenile Diabetes (S.T., L.L.), Meyer Pediatric Hospital, Florence 50132, Italy; Institute of Biomedicine of Valencia (CSIC) and CIBERER-ISCIII (M.A.G.-G., P.S.), Valencia 46010, Spain; Pediatric and Adolescent Unit (P.B.), S. Anna Hospital, Ferrara, Italy; and Molecular Biology and Biochemistry Department (J.C.A.). University of Málaga, Málaga 29071, Spain

Glucokinase is essential for glucose-stimulated insulin release from the pancreatic β-cell, serving as glucose sensor in humans. Inactivating or activating mutations of glucokinase lead to different forms of glucokinase disease, i.e. GCK-monogenic diabetes of youth, permanent neonatal diabetes (inactivating mutations), and congenital hyperinsulinism, respectively. Here we present a novel glucokinase gene (GCK)-activating mutation (p.E442K) found in an infant with neonatal hypoglycemia (1.5 mmol/liter) and in two other family members suffering from recurrent hypoglycemic episodes in their childhood and adult life. In contrast to the severe clinical presentation in the index case, functional studies showed only a slight activation of the protein (relative activity index of 3.3). We also report on functional studies of two inactivating mutations of the GCK (p.E440G and p.S441W), contiguous to the activating one, that lead to monogenic diabetes of youth. Interestingly, adult family members carrying the GCK pE440G mutation show an unusually heterogeneous and progressive diabetic phenotype, a feature not typical of GCK-monogenic diabetes of youth. In summary, we identified a novel activating GCK mutation that although being associated with severe neonatal hypoglycemia is characterized by the mildest activation of the glucokinase enzyme of all previously reported. (Molecular Endocrinology 23: 1983–1989, 2009)
betes as in the case of individuals with homozygous or compound heterozygous mutations. The resulting clinical phenotype of partial glucokinase deficiency is GCK-monogenic diabetes of youth (GCK-MDY, a newly proposed nomenclature), also known as maturity onset diabetes of the young 2 (MODY2) (2), whereas complete glucokinase deficiency leads to permanent neonatal diabetes mellitus (GCK-PNDM) (3, 4). On the contrary, the GSIR-T in carriers of activating mutations of GCK decreases, causing hypoglycemia (GCK-HI) due to inappropriate insulin secretion when plasma glucose is below the normal GSIR-T, featuring mild or severe forms of the disease (5–8). These different GCK-linked disorders of glucose metabolism (GCK-MDY, GCK-PNDM, and GCK-HI) are the three different forms of glucokinase disease.

Glucokinase disease can be caused by missense GCK mutations located anywhere in the primary sequence with no major hot spots defined (9, 10). However, GCK-HI mutations cluster in the small domain of GK protein, where the allosteric activator site is located (11).

In this manuscript we present a novel activating GCK mutation that, in spite of presenting the lowest relative activity index (% AI) and the highest predicted GSIR-T of all naturally occurring GK activating mutations described so far, leads to severe neonatal hypoglycemia (1.5 mmol/liter). Furthermore, we also report functional studies of contiguous inactivating mutations in GCK that lead to the hyperglycemic form of the glucokinase disease (GCK-MDY).

Results

Identification of missense mutations in the GCK gene

Family trees of the three patients carrying the GCK mutations studied in this report are depicted in Fig. 1. Denaturing gradient electrophoresis experiments showed abnormal patterns of PCR products of exon 10 of the GCK in all affected families' members available for analysis. We identified three missense mutations in the heterozygous state. A novel mutation in codon 442, with lysine substituting for glutamic acid (p.E442K) in the proband of family GCK-HI-1 (subject III-2 in Fig. 1A), as well as in her affected brother and mother (subjects III-1 and II-1 in Fig. 1A). A single nucleotide change resulting in a tryptophan for serine substitution at codon 441 (p.S441W) was found in the proband of family FE-11 (subject III-1 in Fig. 1B), in his younger brother, his mother, and maternal grandmother (Fig. 1B). This mutation had been previously described in another Italian family (10). Finally, a novel mutation resulting in a substitution of glutamic acid by glycine at codon 440 (p.E440G) was found in the proband of family FI-10 (subject III-1 in Fig. 1C), in his younger brother, in his father, and in a paternal uncle (Fig. 1C). None of the mutations were found in the chromosomes of 100 healthy chromosomes.

Metabolic features of families with GK disease

Family GCK-HI-1 (p.E442K)

The proband with hypoglycemia (Subject III-2 in Fig. 1A) was born at the 41st week of gestation and presented at d 1 of life with plasma glucose of 1.5 mmol/liter. Her birth weight was 2840 g, and the clinical examination was unremarkable. Family history disclosed that the maternal grandfather and the mother, as well as the eldest brother, presented with recurrent, symptomatic hypoglycemic-like episodes characterized by cold sweating, pallor, fatigue, hunger, and tachycardia; in addition, the mother and the brother of the index case showed fasting plasma
glucose of 2.2–3.0 mmol/liter on several occasions. At the age of 3 wk (weight, 4200 g) the proband was referred to the Metabolic Unit of Bambino Gesù Pediatric Hospital for further investigation. At that time her plasma glucose ranged between 1.9 and 4.3 mmol/liter. She had normal plasma values of ammonia, lactate, triglycerides (122 mg/dl), and total cholesterol (130 mg/dl). The urine excretion of α-ketoglutarate, another marker of HI due to gain-of-function mutations of glutamate dehydrogenase gene (12), was normal, as well as blood acylcarnitines, amino acids, and serum transferrin isoelectric focusing. Abdominal and brain ultrasonography were also normal. After i.m. glucagon (1 mg), plasma glucose rose from 2.2 to 6.0 mmol/liter; simultaneous baseline evaluation of plasma cortisol (23 μg/dl), IGF-I (237 ng/ml), and ACTH (35 pg/ml) were all normal. These clinical investigations combined excluded some causes of hypoglycemia. Low-dose diazoxide therapy (2 mg/kg d), which normalized blood glucose, was started in the proband and was continued for 3 months. The patient, now 6 yr old and on diet therapy only, did not suffer from any other symptomatic hypoglycemia; in contrast, the patient’s elder brother experienced, in the same time interval, two unexplained syncopal episodes.

**Family FE-11 (S441W)**

All the affected members of this family (Fig. 1B) presented impaired fasting glucose (IFG) (6.5–6.9 mmol/liter), and all were treated only with diet. The oral glucose tolerance test (OGTT) carried out in the proband (Fig. 1B, subject III-1) showed impaired glucose tolerance and low plasma insulin at 30 min (18 μU/ml with corresponding plasma glucose of 10 mmol/liter) (Table 1), a result, which is typically found in GCK-MDY patients.

**Family FI-10 (E440G)**

The proband and his younger brother presented IFG (6.1 and 5.8 mmol/liter, respectively) (Fig. 1C, subjects III-1 and III-2). Intravenous glucose tolerance test (IVGTT)-derived first-phase insulin response (FPIR) of children carrying the p.E440G mutation showed unexpectedly high figures of 308 and 241 μU/ml (Table 1). These values, respectively, exceed the 97th (260.7 μU/ml) and the 90th (223.7 μU/ml) centile of normal Italian children of corresponding pubertal status (13). This high FPIR was observed again in both brothers when the IVGTTs were repeated 2 yr later (310 and 215 μU/ml, respectively) (Table 1). In addition, adult family members carrying the mutation showed a diabetic phenotype, not typical of GCK-MDY, with the proband’s father presenting high fasting plasma glucose (10.4 mmol/liter) and a paternal uncle treated with oral hypoglycemic agents; unfortunately, two other paternal uncles, one treated with oral hypoglycemic agents (OHA) and another with insulin, were not available for genetic analysis (Fig. 1).

**Kinetic analysis of recombinant wild-type (WT) and mutant glucokinase**

Kinetic properties of WT and mutant GK are shown in Table 2. Mutation GK-E442K showed a higher affinity for glucose ($\frac{S_{0.5}}{K_m}$ 4.43 mmol/liter) than GK-WT and a relative activity index (% AI) that was more than 3 times higher (Table 2), indicating that K442 is an activating mutation. On the contrary, mutations GK-E440G and GK-S441W showed a lower affinity for glucose, ($\frac{S_{0.5}}{K_m}$ 10.85 and 15.89 mmol/liter, respectively), as compared with GK-WT. The lowest affinity for the second substrate MgATP$^{2-}$, catalytical activity and cooperativity index (Hill number $n_H$), were found in mutation GK-S441W.

<table>
<thead>
<tr>
<th>Family/mutation</th>
<th>Age (yr)</th>
<th>BMI (kg/m$^2$)</th>
<th>IVGTT FPIR (μU/ml)</th>
<th>OGTT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FI-10/E440G</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subject III-1</td>
<td>1997</td>
<td>10</td>
<td>17.5</td>
<td>308</td>
</tr>
<tr>
<td></td>
<td>1999</td>
<td>12</td>
<td></td>
<td>310</td>
</tr>
<tr>
<td>Subject III-1</td>
<td>1997</td>
<td>8</td>
<td>17.2</td>
<td>241</td>
</tr>
<tr>
<td></td>
<td>1999</td>
<td>10</td>
<td></td>
<td>215</td>
</tr>
<tr>
<td><strong>FE-11/S441W</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subject III-1</td>
<td>10</td>
<td>n.a.</td>
<td>16.2</td>
<td>96</td>
</tr>
<tr>
<td><strong>MI-34/S441W</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proband (9)</td>
<td>9</td>
<td>n.a.</td>
<td>16.2</td>
<td>96</td>
</tr>
</tbody>
</table>

The results of the proband MI/S441W presented in this table have been previously reported by Massa et al. (9). n.a.; not available; BMI, body mass index; FPG, fasting plasma glucose; PG, plasma glucose; FPIR, first phase insulin release; IVGTT, intravenous glucose tolerance test; IRI, immunoreactive insulin.

**TABLE 1.** Results of the metabolic studies performed in the probands with GCK-MDY
TABLE 2. Functional characteristics of the recombinants (GK-WT), and the naturally occurring mutations GK-E440G, GK-S441W, and GK-E442K

<table>
<thead>
<tr>
<th>Recombinants GK-WT and mutations</th>
<th>$S_{o.5}$ (mmol/liter)</th>
<th>nH (unitless)</th>
<th>$ATP_{Km}$ (mmol/liter)</th>
<th>$K_{cat}$ (sec$^{-1}$)</th>
<th>Relative activity index (% AI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>7.97 ± 0.31</td>
<td>1.71 ± 0.07</td>
<td>0.45 ± 0.05</td>
<td>65.57 ± 7.19</td>
<td>1</td>
</tr>
<tr>
<td>E440G</td>
<td>10.85 ± 0.68</td>
<td>1.52 ± 0.03</td>
<td>0.74 ± 0.04</td>
<td>51.55 ± 4.64</td>
<td>0.41</td>
</tr>
<tr>
<td>S441W</td>
<td>15.89 ± 2.49</td>
<td>1.38 ± 0.07</td>
<td>1.12 ± 0.14</td>
<td>20.72 ± 4.56</td>
<td>0.11</td>
</tr>
<tr>
<td>E442K</td>
<td>4.43 ± 0.17</td>
<td>1.6 ± 0.05</td>
<td>0.72 ± 0.1</td>
<td>41.98 ± 6.20</td>
<td>3.33</td>
</tr>
</tbody>
</table>

Data are means ± se from three separate enzyme preparations. $ATP_{Km}$, Michaelis constant for ATP; $K_{cat}$, catalytic constant; nH, Hill coefficient.

(45x586) The % AI of GK-E440G and GK-S441W were almost 60% and 90% lower than GK-WT. Consequently, the calculated GSIR-T of MDY-causing mutations GK-E440G and GK-S441W was higher than GK-WT (5.82 and 6.63 mmol/liter vs. 5 mmol/liter, respectively), whereas calculated GSIR-T of the activating mutation GK-E442K was lower (4.14 mmol/liter) than GK-WT (Fig. 2).

Prediction of structural effects of naturally occurring glucokinase mutations

We introduced the mutated residues into the closed active and super-open inactive glucokinase β cell-specific structure models described by Kamata et al. (14) and then compared mutated GK-G440, GK-W441, and GK-K442 with GK-WT. In Kamata’s model the side chain of Glu 442 (E442) is exposed to the solvent in both closed and super-open conformations. The mutant Lys residue in GK-HI-causing K442 would also be exposed to the solvent in both conformations (Fig. 3A). However, the positive charge of the side chain of the Lys 442 residue may interact with the negative charge of Glu 216 residue (E216), stabilizing the closed conformation. In addition, in the super-open conformation (Fig. 3A), the side chain of Lys 442 would be closer to Ala 454 residue (A454), destabilizing the super-open conformation. As a result, the structure of K442 enzyme would favor the closed, active conformation and would consequently lead to higher glucose affinity.

The change of Glu 440 residue (E440) by Gly residue (G440) (Fig. 3B) would destabilize the structure of the protein, because Gly residues are prone to modify the conformation of a particular structure. This interpretation would explain the observed reduction in glucose and
MgATP$^{2-}$ affinity. In the case of the S441W mutation (Fig. 3C, W441), the new bulkier tryptophan residue would be projected toward the inside of the protein, destabilizing it because of its interaction with the α5 helix. This would cause a dramatic reduction in glucose affinity, as observed in in vitro experiments.

**Discussion**

In this report we present a novel activating GCK mutation (p.E442K) in a newborn with severe neonatal hypoglycemia. She is now 6 yr old, in good general condition, and treated with diet therapy only. Her older brother and mother, also bearing the same GCK mutation, did not present hypoglycemia in the neonatal period but repeated episodes of symptomatic hypoglycemia later in life. Functional studies of mutated protein showed an enzyme with almost a 2-fold increase in glucose affinity compared with GK-WT. The E442 residue is located in a loop between the β13 and α13 domains of GK. According to Kamata’s model (14), this loop plays an important role in the conformational change of the GCK from the super-open to the closed active conformation of the enzyme. Although E442 does not participate directly in the binding to the allosteric activator (compound A in Kamata’s model) (14), the K442 mutation favors the transition to the closed conformation of the enzyme, leading to increased glucose affinity (Fig. 3A). The structural analysis along with the calculated % AI and GSIR-T (3.3 and 4.14 mmol/liter, respectively) obtained from the experimental data, indicate that the activation of GK caused by the E442K mutation is the cause of hypoglycemia in the proband and in other members of the family carrying the mutation (Fig. 1A).

Recently, a de novo GCK-activating mutation (HI-GCK-M197I) has been described in a child that presented severe neonatal hypoglycemia (8). Interestingly, the in vitro studies also showed a mild activation of GK-M197I (8). Therefore, our mutation HI-GCK-E442K is another good and confirmatory example of the discrepancy one may find between the severity of the clinical phenotype at presentation and the data resulting from the functional analysis in vitro of the mutated enzyme. Indeed, the results of the kinetic (in vitro) analysis of mutation GK-E442K showed the lowest % AI as well as the highest GSIR-T of all naturally occurring GCK activating mutations described to date (11, 15). This is in line with the relatively mild symptoms of hypoglycemia shown in affected members in childhood and adult life, but in contrast to the severe clinical onset presented by the proband. We can only speculate that the proband could have some transient immaturity of glucoregulatory pathways that contributed to lower her plasma glucose levels. However, we do not believe that this may be ascribed to the relatively low birth weight of the proband, which was in line with that reported in other patients with activating GCK mutations born from affected mothers (16).

We also described two inactivating GCK mutations (p.E440G, p.S441W) contiguous to the activating p.E442K. Patients carrying the mutation p.S441W present a phenotype highly characteristic of GCK-MDY patients, i.e. IFG combined with impaired glucose tolerance with low values at tests evaluating (early) insulin release (17). In contrast, the two young and lean brothers carrying the mutation p.E440G showed high plasma insulin levels at 30 min of OGTT and in two independent IVGTT tests (Table 1). Like the family previously reported with GCK-MDY (mutation p.L184P) (18), we also observed some metabolic heterogeneity within the different E440G carriers of family FI-10 (Fig. 1). As a matter of fact, although functional and structural studies of GK-E440G (Table 2) fully explain the basic metabolic features of the proband and his brother, they are not sufficient to clarify the severe diabetic phenotype observed in adult family members carrying the mutation. Thus, the coexistence of other unknown genes implicated in glucose metabolism or unrecognized environmental factors should be considered in these kindred.

In summary, we identified a novel activating GCK mutation that, although being associated with severe neonatal hypoglycemia, is characterized by the mildest activation of the glucokinase enzyme of all previously reported. In addition, the coexistence of unknown genes implicated in glucose metabolism or unrecognized environmental factors could be the cause of the metabolic heterogeneity presented by different carriers of the same inactivating GCK-E440G mutation.

**Materials and Methods**

**Subjects**

The proband with hypoglycemia (Subject III-2 in Fig. 1A) was referred to the Metabolic Unit of Bambino Gesù Children’s Hospital for diagnostic workup. Routine laboratory examinations were all normal with the exception of insulin, which was inappropriately high (12 μU/ml) for the corresponding plasma glucose. Family history disclosed that her elder brother and mother (subjects III-1 and II-1 in Fig. 1A) suffered repeated episodes of symptomatic hypoglycemia, and the maternal grandfather (deceased, not tested) had hypoglycemia-like symptoms (i.e. sweatiness, headache, hunger, and weakness).

The diabetic probands studied in this report were identified during the course of an Italian nationwide project aimed at selecting patients with monogenic diabetes (subjects III-1 in Fig. 1, B and C) out of subjects referred to pediatric diabetes clinics for incidental hyperglycemia (10, 19).
Metabolic studies

Probands of families with (GCK-MDY) (subjects III-1 in Fig. 1, B and C) underwent two tests as part of the protocol for studying subjects with incidental hyperglycemia: a standard OGTT with serum insulin determinations and an IVGTT. IVGTT was performed injecting 0.5 g of glucose per kg/body weight. Blood samples were taken at −15, 0, and 1, 3, 5, and 10 min after the glucose injection for plasma insulin determination. FPIR was calculated as the sum of insulin immunoreactivity at min 1 and min 3, and the result was compared with those obtained in normal Italian children according to their pubertal stage (13). Insulin assay was not centralized. However, other IVGTT tests performed in the same center of family FI-10, on probands with mutations in the GCK, always elicited low FPIR (see Table 1). All tests were approved by the local institutional ethics committee, and a written informed consent was obtained from the parents of the probands.

Molecular genetic studies

Genomic DNA was extracted from peripheral lymphocytes. The complete coding sequence of the GCK was amplified by the PCR and analyzed by denaturing gradient electrophoresis as previously described (10). In the proband clinically defined as having hyperinsulimemic hypoglycemia and his relatives, screening of GCK gene was performed first, based on the autosomal-dominant mode of inheritance of hypoglycemia (5, 11). We excluded the possibility of mutations of the glutamate dehydrogenase gene (GDH) because of the normal plasma ammonia concentrations (20). The PCR products showing abnormal electrophoretic pattern were subjected to direct sequencing by an ABI DNA sequencing apparatus 373A (PerkinElmer Applied Bio Systems, Foster City, CA). Mutations were confirmed in all affected family members available for analysis.

Site-directed mutagenesis

Mutations p.E440G, p.S441W, and p.E442K on GCK were introduced into the WT human pancreatic GCK using the QuikChange Site-Directed Mutagenesis kit from Stratagene (La Jolla, CA) (oligonucleotide sequences available upon request). Plasmid pUC-Gk keto was used as a template in the PCRs. All plasmids were sequenced to confirm that only the desired mutation had been introduced. Mutated plasmids (pUC-Gk keto-E440G, S441W, and E442K) were digested with EcoRI and SalI, and the insert was cloned into plasmid pGEX-6P-1 (Amersham Pharmacia, Piscataway, NJ), to allow its expression in Escherichia coli as a glutathionyl S-transferase fusion protein. Purified recombinant glutathionyl S-transferase-GK was routinely screened for purity by SDS-PAGE.

Kinetic and structural analysis of the GK protein

Studies of the kinetic properties of and GK-E440G, GK-S441W, and GK-E442K in the presence of 2 mmol of dithiothreitol per liter of reaction mixture were performed spectrophotometrically as described previously (21). At least three different preparations of GK-WT and GK-mutants were made and analyzed. We used nonlinear kinetics according to the Hill equation to determine the affinity of the enzyme for glucose and the Hill coefficient that characterizes the sigmoidal glucose dependency of GK. To measure the glucose phosphorylation capacity of the enzyme, we used the relative activity index, which was calculated according to the formula previously reported (11). The structural analysis of the activating mutation was carried out using the crystal structure of human GK (14).

Mathematical modeling

We used a minimal mathematical model (1, 11, 21) to assess the impact of GK mutations on GSIR-T. We determined the impact of blood glucose levels on GK expression for both WT and mutated alleles by using the expression coefficient for either allele: $e = \frac{S_{0.5}^*}{(S^{*} + S_{0.5}^*)} = 2$, where $S$ refers to the glucose level at threshold, $nH$ is the Hill coefficient for cooperativeness with glucose, the numerical value of 2 indicates that half-maximal induction is achieved at glucose $S_{0.5}$, and $S_{0.5}$ refers to the concentration of glucose needed to achieve the half-maximal rate of phosphorylation (1, 11).

Acknowledgments

We thank all family members who participated in this study. Address all correspondence and requests for reprints to: Fabrizio Barbetti, M.D., Ph.D., Tor Vergata University Hospital, Laboratory Medicine, First floor, Section D, Room 118, Viale Oxford 81, 00134 Rome, Italy. E-mail: mody.2@libero.it or fabrizio.barbetti@spr-r.it; and Antonio Cuesta-Munoz, M.D., Ph.D., Center for the Study of Pancreatic β-Cell Diseases. IMABIS Foundation and Carlos Haya Hospital. Avda. Carlos Haya 82, Pabellón A-7 planta 29010 málaga, Spain. E-mail: alcem@fundacionimabis.org.

F.B, S.T., and P.B. are members of the Diabetes Study Group of the Italian Society of Pediatric Endocrinology and Diabetology (SIEDP). This work was supported by grants (to A.L.C.-M. and N.C.-V.) from Ministerio de Ciencia e Innovación, Dirección General de Investigación Científica y Técnica (SAF2005-08014; SAF2006-12863) and Junta de Andalucía (SAS/PI-024/2007; SAS/PI-0236/2009).

Disclosure Summary: The authors have nothing to disclose.

References

18. Fajans SS, Bell GI 2006 Phenotypic heterogeneity between different mutations of MODY subtypes and within MODY pedigrees. Diabetologia 49:1106–1108